

Preliminary Programme

- Keynote** Tracking Cancer by Liquid Biopsy –
address: 15 Years Adventure
- Session 1:** Cancer Biology & Metastasis
- Session 2:** Cancer Immunobiology & Microbiome
- Session 3:** Early Detection of Cancer
- Session 4:** Minimal Residual Cancer Detection
and Characterization
- Session 5:** Liquid Biopsy and Immuno-Oncology
- Session 6:** Risk Assessment & Monitoring of Cancer Therapies
- Session 7:** Perspective of Liquid Biopsy

Host



IHU RespirERA
CHU of Nice, 4 Avenue Victoria
06000 Nice Cedex, France

Co-Host



Venue

Hyatt Regency Nice Palais de la Méditerranée
13 Promenade des Anglais
06011 Nice Cedex 1, France

Congress and Exhibition Office



Hanser & Co GmbH
Barsbüttel, Germany
Tel.: +49 40 670882-0
ismrc@cpo-hanser.de

Deadlines

Abstract Submission Deadline: ▶ 26 Feb 2025
Early Bird Registration Deadline: ▶ 12 Mar 2025

www.ismrc-symposium.eu



ISMRC 2025

**14th International Symposium
on Minimal Residual Cancer**

Liquid Biopsy: From Discovery to
Clinical Implementation

7 – 9 May 2025

Hyatt Regency Nice Palais de la Méditerranée
Nice, France



www.ismrc-symposium.eu



Dear Colleagues and Friends,

It is a real pleasure for us to warmly welcome you to the 14th International Symposium on Minimal Residual Cancer (ISMRC) in Nice, France.

The ISMRC meetings were initiated almost 25 years ago in 1996 by Klaus Pantel, and, represent now a major event in the world related to many aspects of Liquid Biopsy in cancer patients.

This international meeting is a fantastic opportunity to gather for three days and share many updated aspects concerning the use of liquid biopsies in cancer patients. Moreover, this meeting covers many new developments of liquid biopsy for clinical implementation, with some specific focuses on the role of liquid biopsy in treatment decision making both for immuno-oncology and targeted therapies. Moreover, special sessions will be dedicated to the new aspects of minimal residual disease detection, early detection and screening cancers, and monitoring disease by blood sampling for tracking resistance mechanisms to different therapeutic.

The congress will include also more fundamental and translational presentations on different liquid biopsy components (Circulating Tumor Cells, exosomes, miRNA and circulating free DNA). Additionally the perspective of liquid biopsy for the next few years will be presented. The 2025 meeting in Nice is supported by the European Liquid Biopsy Society (ELBS) and the new Institut RespirERA created in Nice (IHU RespirERA).

Plenary presentations will be given by leading international experts in different fields of liquid biopsy, as well as in cancer biology. Moreover, the ISMRC strongly supports young investigators through selected oral communications as part of plenary sessions but also poster presentations. Importantly, outstanding oral and poster presentations will be awarded with our Young investigator awards.

We look forward to welcoming you to Nice in May 2025!

Sincerely,
Paul Hofman
Catherine Alix-Panabières and
Klaus Pantel



Prof. Dr. Paul Hofman
Congress Chair



Prof. Dr. Catherine
Alix-Panabières, Co-Chair



Prof. Dr. med.
Klaus Pantel, Co-Chair

Confirmed Speakers

Catherine Alix-Panabières, France	Sonja Loges, Germany
Fabrice André, France	Raphael Lopez Lopez, Spain
Benjamin Besse, France	Umberto Malapelle, Italy
Joanna Budna, Poland	Nuria Malats, Spain
Luis Diaz, USA	Joan Massagué, USA
Yuval Dor, Israel	Koshi Mimori, Japan
Janine Erler, Denmark	Clara Montagut, Spain
Sidonia Fagarasan, Japan	Nicola Normanno, Italy
Karen-Lise Garm-Spindler, Denmark	Nickolas Papadopoulos, USA
Paola Gazzaniga, Italy	Klaus Pantel, Germany
Christoffer Gebhardt, Germany	Jean-Yves Pierga, France
Simon Heeke, USA	Nitzan Rosenfeld, United Kingdom
An Hendrix, Belgium	Carolyn Sauer, United Kingdom
Paul Hofman, France	Lillian L. Siu, Canada
Laura Keller, France	Charles Swanton, United Kingdom
Bob T. Li, USA	Jean-Paul Thiery, France
	Alexander Wyatt, Canada

Chair

Prof. Dr. Paul Hofman
IHU RespirERA, CHU of Nice, France



Co-Chairs

Prof. Dr. med. Klaus Pantel
Institute of Tumor Biology, University
Medical Center Hamburg-Eppendorf, Germany

Prof. Dr. Catherine Alix-Panabières
Laboratoire Cellules Circulantes, Rares
Humaines (LCCRH), CHU de Montpellier, France

